Of particular interest to us is RUNX1/ETO, a fusion gene found in Acute Myeloid Leukaemia (AML) cells and which acts as a regulator of transcription without intrinsic enzymatic activity, making it a difficult target for conventional drug development programmes, but an ideal target for siRNA therapy [5,6]. The gene discussed is RUNX1; the disease is acute myeloid leukemia.